Francesca Colapietro

On Earth since 1990. Liver focused PhD student and Internal Medicine Physician in Milan, Italy

[Ramon Bataller @rabataller]

I was walking in Barcelona to my hospital and saw a fantastic young crow attending the EASL School on interpretation of liver biopsy for hepatologists.

Thanks to Xavi Forns and Alba Diaz for organizing it !!

#barcelonaeasl #livertwitter @EASLedu @EASLnews

[Jesus Bañales @JesusMBanales]

1/🚀JHEP Journal Club🚀

🤔What factors determine the risk of HCC in👫with autoimmune hepatitis (AIH)❓
🔓https://t.co/a26rYyHE3z

AIH
👉rare chronic liver disease
👉unclear etiology

@analleo & the Int AIH Group🔍 1428 🌍patients 👇👇👇
#livertwitter

[ERN RARE LIVER @ERN_RARE_LIVER]

🚀 The mission of @ERN_RARE_LIVER is to improve the care of rare liver disease patients throughout Europe.
🎗️ To support Rare Disease Day we also share the stories of our patients, such as our #ERNYouthPanel Series on YouTube:
https://t.co/eDw6pQHX2h

🔗 https://t.co/6xnoY1IHnZ

[Ana Lleo @analleo]

@CcaEns @CharityAMMF @curecc

[Journal of Hepatology @JHepatology]

🆕Article in press❕

Incidence and predictors of #hepatocellularcarcinoma in patients with #autoimmunehepatitis

Read it here👉https://t.co/oBYgFvHcj8

#LiverTwitter

[Nicola Pugliese @nicolapugliese_]

📣Check out our new paper on @AGA_CGH about potential role of #chatGPT 💬 as counselling tool for #NAFLD/#MASLD patients! 🎯

@AghemoAlessio @GiadaSebastiani @VWSWong @schattenbergJ @mromerogomez @lucavalenti75 @salvatore_petta @penny_manousou @lmiele74

https://t.co/zl1anKoEwD

[Francesca Colapietro @F__Colapietro]

Grazie ad AISF per l’opportunità di presentare questi dati, frutto dell’impegno dei colleghi membri dell’ IAIHG, che ringrazio ancora e sempre

[AISF - Associazione Italiana Studio Fegato @AisfFegato]

Qual è il rischio, per i pazienti affetti da epatite autoimmune, di sviluppare epatocarcinoma? Ce ne ha parlato la dott.ssa Francesca Colapietro, Humanitas University, Milano, in occasione del 55° Congresso AISF... https://t.co/OfXM1QOOxJ

[Journal of Hepatology @JHepatology]

📢HEAL study❗️

Weekly #albumin infusion in individuals with #cirrhosis improved
✅quality of life
✅endothelial dysfunction
✅inflammation
➡️albumin levels & cognitive benefit persisted after ending infusions

Read it here👉https://t.co/drUDjePVRf

@JasmohanBajaj
#LiverTwitter

[massimo iavarone @massimoiava]

@AlessioGerussi giving a practical lecture of #DILI in #Immunotherapy at annual meeting... "to biopsy or to treat" @AisfFegato #HCC #LiverTwitter

[Journal of Hepatology @JHepatology]

📢HEAL study❗️

Weekly #albumin infusion in individuals with #cirrhosis improved
✅quality of life
✅endothelial dysfunction
✅inflammation
➡️albumin levels & cognitive benefit persisted after ending infusions

Read it here👉https://t.co/drUDjePVRf

@JasmohanBajaj
#LiverTwitter

[Journal of Hepatology @JHepatology]

🆕Article in press❕

#HepatocellularCarcinoma risk in patients with chronic #hepatitisB receiving #tenofovir-🆚 #entecavir-based regimens: Individual patient data meta-analysis

🔓#OpenAccess at👉https://t.co/zghI5CpM1T

#LiverTwitter

[Francesca Colapietro @F__Colapietro]

#KarolinskaInstitutet and snow

[Journal of Hepatology @JHepatology]

🆕EXPERT OPINION

Treatment of #portalhypertension in patients with #HCC at the era of #Baveno VII

By Dominique Thabut & Masatoshi Kudo

Read it here👉https://t.co/djNoEirVsi

@BrainLIverPS
@BavenoVII
#LiverTwitter

[ERN RARE LIVER @ERN_RARE_LIVER]

📢Don't miss our next Webinar❗️
✅The new EASL Clinical Practice Guidelines on sclerosing cholangitis
📅29 November 2022, 18:00 CET
Register here: https://t.co/UwxSgBjnoO

#LiverTwitter #MedTwitter #ERNRARELIVER #sharecarecure #sharingexpertise

[JHEP Reports @JHEP_Reports]

🟪NEW Article in press❕

Long-term results of #MycophenolateMofetil 🆚 #azathioprine use in patients with #AutoimmuneHepatitis

🔓#OpenAccess at👉https://t.co/8ifziCtbQa

#LiverTwitter

[EASLnews @EASLnews]

What does the future hold for #PBC therapies?
Find out today with #EASLStudio!
🔗 https://t.co/Zywva2Zf4H

#Livertwitter #PBCDay2022
@EASLEdu @EASLEUaffairs @GSK @IpsenGroup @CymaBay @AutoimmuneLiver @AnaLleo @PBCFoundation @PBCRobert @PBCers @GlobalLiver

[JHEP Reports @JHEP_Reports]

🟪NEW Article in press❕

Quantitative magnetic resonance #cholangiopancreatography metrics are associated with disease severity and outcomes in patients with #PrimarySclerosingCholangitis

🔓#OpenAccess at👉https://t.co/GpbPoqNBWg

#LiverTwitter

[Arndt Vogel @ArndtVogel]

🔥FDA approves durvalumab for locally advanced or metastatic biliary tract cancer🔥

👉great news for our patients👏👏
👉waiting for EMA... again ....

@myESMO @EASLedu @OncoAlert #livertwitter #cholangiocarcinoma @CcaEns #Immunotherapy

[Joost PH Drenth @joostphdrenth]

I wish to congratulate @Alexfornergon @AghemoAlessio and @lucavalenti75 with the new (and substantially higher) impact factor of @LiverInt 8.754 ✅ This team makes a difference for the #livertwitter field 🙏 for the great work @wileyhealth 👉 Congratulations @ReibergerThomas

[Francesca Colapietro @F__Colapietro]

Proud to share data📊 on our latest study on incidence and predictors of HCC in a large and multicentric AIH cohort! #ILC2022

[Nicola Pugliese @nicolapugliese_]

Very ⬇️ risk of #HCC development in #AIH 🔴⬆️ risk in >40yo, obese, cirrhotic or AIH-PSC patients 🔴 My colleague and friend @F__Colapietro at #ILC2022 @HumanitasMilano @HUNIMED @EASLnews